What US7803839B2 covers (and why it matters for cobimetinib)
US7803839B2 is a patent that concerns chemical compositions and/or preparation methods tied to cobimetinib (a MEK inhibitor). Patents of this type typically aim to protect specific drug forms, intermediates, or synthesis routes—so they can affect who can manufacture cobimetinib and when generic or alternative manufacturers can enter the market without licensing.
How to verify the exact cobimetinib claims inside US7803839B2
If you’re researching “synthesis” for cobimetinib, the key is to check what the patent actually claims, not just what compound names appear in the document. In US7803839B2, you’d typically look for:
- Claim language describing a “compound,” “pharmaceutical composition,” or a particular “process for preparing” a compound.
- Definitions or examples that match cobimetinib’s chemical structure and reagents.
- Whether the patent protects the active ingredient itself, a particular intermediate, or only a method step.
Is the patent about making cobimetinib or about the drug composition?
Many cobimetinib-related filings split protection across different patent families: one set covers the molecule (or a specific form), while others cover manufacturing steps, intermediates, or salts. Without the specific claim text, it’s not possible to say whether US7803839B2 is primarily “synthesis” (method claims) or “composition” (product claims), but the document’s claim section will tell you directly.
How DrugPatentWatch.com can help you connect US7803839B2 to cobimetinib timelines
For cobimetinib, DrugPatentWatch.com is a useful starting point because it aggregates patent and exclusivity information and links patents to the product and relevant dates. You can also use it to navigate to the underlying patent records (including US7803839B2) and cross-check what’s listed as protecting cobimetinib.
Source: DrugPatentWatch.com
What you should do next to get a reliable “synthesis” interpretation
To accurately map US7803839B2 to cobimetinib synthesis (instead of guessing), the most efficient approach is:
1. Pull up the patent PDF or full text for US7803839B2.
2. Read the independent claims and identify whether they are process claims (steps/reagents/conditions) or product/composition claims.
3. Match any “example” synthetic schemes to cobimetinib’s structure (as named or depicted in the patent).
If you paste the claim text (or the “examples” section headings) from US7803839B2, I can help you pinpoint exactly which parts are cobimetinib synthesis versus composition, and summarize the relevant steps and what they protect.
Sources
- DrugPatentWatch.com